Revenue and Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Revenue and Segment Information [Abstract]

Schedule of Changes in Accounts Receivable

The following table presents changes in the Company’s accounts receivable for the three months ended March 31, 2025:

	Balance as of December 31, 2024		Additions		Deductions			Balance as of March 31, 2025
Accounts receivable	$	706,925	$	1,101,605	$	(1,116,287	)	$	692,243

Schedule of Information from the Consolidated Statements of Operations and Comprehensive Loss

Select information from the consolidated statements of operations and comprehensive loss as of the three months ended March 31, 2025 and 2024 is as follows:

	Revenues				Net Loss Before Allocation to Noncontrolling Interest
	Three Months Ended March 31,				Three Months Ended March 31,
Segment	2025		2024		2025			2024
Specialist isotopes and related services	$	1,101,605	$	840,354	$	(6,389,533	)	$	(4,643,494	)
Nuclear fuels		—		—		(2,093,649	)		(2,079,007	)
Corporate		—		—		21,750			(242,343	)
	$	1,101,605	$	840,354	$	(8,461,432	)	$	(6,964,844	)

Schedule of Reconciliation of Total Segment Revenue to Total Consolidated Revenue and of Total Segment Gross Profit and Segment Operating Income to Total Consolidated Income Before Income Taxes

A reconciliation of total segment revenue to total consolidated revenue and of total segment gross profit and segment operating income to total consolidated income before income taxes, for the three months ended March 31, 2025 and 2024, is as follows:

	Three Months Ended March 31, 2025
	Specialist isotopes and related services			Nuclear fuels			Corporate			Total
Sales from external customers	$	1,101,605		$	—		$	—		$	1,101,605
Less: cost of sales		(774,765	)		—			—			(774,765	)
Segment gross profit		326,840			—			—			326,840
Personnel expenses		3,300,041			591,243			—			3,891,284
Professional fees		1,968,498			376,029			—			2,344,527
Other segment expenses		1,698,974			344,391			—			2,043,365
Segment operating loss		(6,640,673	)		(1,311,663	)		—			(7,952,336	)
Foreign exchange transaction gain		—			—			(61,470	)		(61,470	)
Change in fair value of share liability		—			—			12,500			12,500
Change in fair value of convertible notes payable		—			(957,408	)		—			(957,408	)
Interest income (expense), net		251,140			175,422			—			426,562
Loss before income tax expense	$	(6,389,533	)	$	(2,093,649	)	$	(48,970	)	$	(8,532,152	)

	Three Months Ended March 31, 2024
	Specialist isotopes and related services			Nuclear fuels			Corporate			Total
Sales from external customers	$	840,354		$	—		$	—		$	840,354
Less: cost of sales		(561,484	)		—			—			(561,484	)
Segment gross profit		278,870			—			—			278,870
Personnel expenses		2,606,446			—			—			2,606,446
Professional fees		1,248,982			1,110,188			—			2,359,170
Other segment expenses		1,128,064			—			—			1,128,064
Segment operating loss		(4,704,622	)		(1,110,188	)		—			(5,814,810	)
Foreign exchange transaction gain		—			—			(24,343	)		(24,343	)
Change in fair value of share liability		—			—			(218,000	)		(218,000	)
Change in fair value of convertible notes payable		—			(953,710	)		—			(953,710	)
Interest income (expense), net		(1,600	)		—			—			(1,600	)
Loss before income tax expense	$	(4,706,222	)	$	(2,063,898	)	$	(242,343	)	$	(7,012,463	)